journal article·2025-02Open access

Cholesterol Targeted Catalytic Hydrogel Fueled by Tumor Debris can Enhance Microwave Ablation Therapy and Anti‐Tumor Immune Response

Lin Shen, Zhijuan Yang, Yi Zhong, Yanran Bi, Junchao Yu, Qinwei Lu, Yanping Su, Xiaoxiao Chen, Zhongwei Zhao, Gaofeng Shu, Minjiang Chen, Liang Cheng, Liangzhu Feng, Chenying Lu, Zhuang Liu, Jiansong Ji

Advanced Science· Volume 12· Issue 5

Abstract

Abstract The immunosuppressive residual tumor microenvironment (IRTM) is a key factor in the high recurrence and metastasis rates of hepatocellular carcinoma (HCC) after microwave ablation (MWA). Cholesterol‐rich tumor fragments significantly contribute to IRTM deterioration. This study developed a cholesterol‐targeted catalytic hydrogel, DA‐COD‐OD‐HCS, to enhance the synergy between MWA and immune checkpoint inhibitors (ICIs) for HCC treatment. Cholesterol oxidase (COD), modified with dimethyl maleic anhydride (DA) for release in acidic IRTM, is used to degrade cholesterol. Oxydextran (OD) and hemin‐chitosan (HCS) formed a dual network gel, ensuring long‐term fixation of COD and hemin in the IRTM post‐MWA. In both in vitro and in vivo HCC models, DA‐COD‐OD‐HCS effectively released COD, degraded cholesterol, and induced tumor cell ferroptosis, enhancing the antitumor immune response. Combined with anti‐PD‐L1 immunotherapy, this strategy inhibited primary tumor growth and distant metastases, without side effects on adjacent tissues. This work highlights that cholesterol‐targeting catalytic hydrogels fueled by tumor debris can significantly improve the efficacy of MWA and ICIs, offering a novel therapeutic approach for HCC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer, Lipids, and Metabolism · Ferroptosis and cancer prognosis · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology The Fifth Affiliated Hospital of Wenzhou Medical University Lishui 323000 P. R. China

Clinical College of The Affiliated Central Hospital School of Medicine, Lishui University Lishui 323000 P. R. China

Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon‐Based Functional Materials & Devices Soochow University Suzhou Jiangsu 215123 P. R. China

Funding

Medical Science and Technology Project of Zhejiang Province · Natural Science Foundation of Zhejiang Province · Postdoctoral Science Foundation of Jiangsu Province · National Natural Science Foundation of China

References (51)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1016/j.jhep.2018.12.00110.1016/j.jhep.2018.12.001 ↗
3. 10.1002/ags3.1206510.1002/ags3.12065 ↗
4. 10.1002/hep.2991310.1002/hep.29913 ↗
5. 10.1126/sciadv.abo528510.1126/sciadv.abo5285 ↗
6. Liang P. · Anticancer Res. · 2015 · 35 · 3
7. 10.1016/j.surg.2017.10.02610.1016/j.surg.2017.10.026 ↗
8. 10.1002/cncr.2419610.1002/cncr.24196 ↗
9. 10.1136/jitc-2019-00041510.1136/jitc-2019-000415 ↗
10. 10.1136/jitc-2021-00234310.1136/jitc-2021-002343 ↗
11. 10.1016/j.diii.2017.12.01110.1016/j.diii.2017.12.011 ↗
12. Hagiwara S. · Cancers · 2016 · 7 · 15
13. 10.1016/j.cmet.2019.04.00210.1016/j.cmet.2019.04.002 ↗
14. 10.1038/s42255-020-0174-010.1038/s42255-020-0174-0 ↗
15. 10.1038/s41586-020-2911-710.1038/s41586-020-2911-7 ↗
16. 10.1038/nm.207410.1038/nm.2074 ↗
17. 10.1038/s41467-021-26718-610.1038/s41467-021-26718-6 ↗
18. 10.1038/s41586-020-2911-710.1038/s41586-020-2911-7 ↗
19. 10.1038/nm.207410.1038/nm.2074 ↗
20. 10.1111/j.1742-4658.2009.07377.x10.1111/j.1742-4658.2009.07377.x ↗
21. 10.1038/cddis.2016.28110.1038/cddis.2016.281 ↗
22. 10.1016/j.yexcr.2021.11294610.1016/j.yexcr.2021.112946 ↗
23. 10.1039/D2NH00070A10.1039/D2NH00070A ↗
24. 10.1016/j.mattod.2022.03.01310.1016/j.mattod.2022.03.013 ↗
25. 10.1038/s41586-019-1170-y10.1038/s41586-019-1170-y ↗
26. 10.1002/smll.20200170410.1002/smll.202001704 ↗
27. Sun L.‐L. · Am. J. Cancer Res. · 2021 · 11 · 5856
28. 10.1139/o89-01010.1139/o89-010 ↗
29. 10.1186/s12951-021-00895-410.1186/s12951-021-00895-4 ↗
30. 10.1038/s41467-021-24604-910.1038/s41467-021-24604-9 ↗
31. 10.1126/sciadv.abo528510.1126/sciadv.abo5285 ↗
32. 10.1021/acsnano.1c1071410.1021/acsnano.1c10714 ↗
33. 10.7150/ijbs.9227410.7150/ijbs.92274 ↗
34. 10.1007/s13668-024-00542-y10.1007/s13668-024-00542-y ↗
35. 10.1016/j.cmet.2019.02.01610.1016/j.cmet.2019.02.016 ↗
36. 10.1016/j.heliyon.2023.e2288510.1016/j.heliyon.2023.e22885 ↗
37. 10.3389/fcell.2021.76282810.3389/fcell.2021.762828 ↗
38. 10.1016/j.apsb.2022.10.02710.1016/j.apsb.2022.10.027 ↗
39. 10.1016/j.msec.2019.04.08110.1016/j.msec.2019.04.081 ↗
40. 10.1007/s41348-018-0181-510.1007/s41348-018-0181-5 ↗
41. 10.1016/j.jare.2022.06.01110.1016/j.jare.2022.06.011 ↗
42. 10.1038/s41467-021-24604-910.1038/s41467-021-24604-9 ↗
43. 10.1016/j.ijbiomac.2022.08.16610.1016/j.ijbiomac.2022.08.166 ↗
44. 10.1016/j.carbpol.2022.11941810.1016/j.carbpol.2022.119418 ↗
45. 10.1016/j.carbpol.2022.12043410.1016/j.carbpol.2022.120434 ↗
46. 10.1016/j.carbpol.2012.06.03710.1016/j.carbpol.2012.06.037 ↗
47. 10.1016/j.carbpol.2021.11894910.1016/j.carbpol.2021.118949 ↗
48. 10.1016/j.foodchem.2022.13458910.1016/j.foodchem.2022.134589 ↗
49. 10.1038/nature1741210.1038/nature17412 ↗
50. 10.1016/j.cmet.2019.04.00210.1016/j.cmet.2019.04.002 ↗
51. Bird L. · Nat. Rev. Immunol. · 2023 · 23 · 413